Empirical treatment of bacterial keratitis: An international survey of corneal specialists

Ariana Austin, Julie Schallhorn, Mike Geske, Mark J Mannis, Tom Lietman, Jennifer Rose-Nussbaumer

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Background/aims New antibiotic agents and changing susceptibility patterns may have changed the empirical treatment of bacterial keratitis. Our objective in this study was to survey cornea specialists' practice patterns in the initial treatment of bacterial ulcers. Methods This study consisted of a short online survey emailed to members of the Cornea Society listserv for an international sample of cornea specialists. Data collection began July 2014 and ended October 2014. Results A total of 1009 surveys were emailed, and we received 140 (14%) responses. The majority of US clinicians surveyed (n=83, 80%) chose fortified antibiotics empirically, with 55% (n=57) selecting fortified vancomycin and 16% (n=17) using fluoroquinolone alone. International respondents were twice as likely to use fluoroquinolone monotherapy (31%, n=11, p=0.07) and less likely to use fortified vancomycin (33%, n=12, p=0.03). Forty-five per cent (n=46) of US respondents reported that their initial antibiotic choice covered methicillin-resistant Staphylococcus aureus, compared with 22% (n=8) of international respondents (p<0.01). Overall, respondents who were concerned about availability of antibiotics and toxicity were 20.86 (p<0.001) and 7.48 (p<0.001) times more likely to choose fluoroquinolone monotherapy, respectively. If respondents' primary considerations were broad spectrum coverage or antibiotic resistance they had 7.10 (p<0.001) and 12.51 (p<0.001) times the odds of using fortified vancomycin, respectively. Conclusion Practice patterns for the initial treatment of bacterial keratitis vary with clinicians in the USA being more likely to use fortified antibiotics versus fluoroquinolone monotherapy and more concerned with resistant organisms than their international peers.

Original languageEnglish (US)
Article numbere000047
JournalBMJ Open Ophthalmology
Volume2
Issue number1
DOIs
StatePublished - Aug 1 2017

Fingerprint

Keratitis
Fluoroquinolones
Anti-Bacterial Agents
Vancomycin
Cornea
Surveys and Questionnaires
Methicillin-Resistant Staphylococcus aureus
Microbial Drug Resistance
Ulcer

Keywords

  • Cornea
  • Infection

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Empirical treatment of bacterial keratitis : An international survey of corneal specialists. / Austin, Ariana; Schallhorn, Julie; Geske, Mike; Mannis, Mark J; Lietman, Tom; Rose-Nussbaumer, Jennifer.

In: BMJ Open Ophthalmology, Vol. 2, No. 1, e000047, 01.08.2017.

Research output: Contribution to journalReview article

Austin, Ariana ; Schallhorn, Julie ; Geske, Mike ; Mannis, Mark J ; Lietman, Tom ; Rose-Nussbaumer, Jennifer. / Empirical treatment of bacterial keratitis : An international survey of corneal specialists. In: BMJ Open Ophthalmology. 2017 ; Vol. 2, No. 1.
@article{bb970ad3e85b4e48afe91b9078f35c73,
title = "Empirical treatment of bacterial keratitis: An international survey of corneal specialists",
abstract = "Background/aims New antibiotic agents and changing susceptibility patterns may have changed the empirical treatment of bacterial keratitis. Our objective in this study was to survey cornea specialists' practice patterns in the initial treatment of bacterial ulcers. Methods This study consisted of a short online survey emailed to members of the Cornea Society listserv for an international sample of cornea specialists. Data collection began July 2014 and ended October 2014. Results A total of 1009 surveys were emailed, and we received 140 (14{\%}) responses. The majority of US clinicians surveyed (n=83, 80{\%}) chose fortified antibiotics empirically, with 55{\%} (n=57) selecting fortified vancomycin and 16{\%} (n=17) using fluoroquinolone alone. International respondents were twice as likely to use fluoroquinolone monotherapy (31{\%}, n=11, p=0.07) and less likely to use fortified vancomycin (33{\%}, n=12, p=0.03). Forty-five per cent (n=46) of US respondents reported that their initial antibiotic choice covered methicillin-resistant Staphylococcus aureus, compared with 22{\%} (n=8) of international respondents (p<0.01). Overall, respondents who were concerned about availability of antibiotics and toxicity were 20.86 (p<0.001) and 7.48 (p<0.001) times more likely to choose fluoroquinolone monotherapy, respectively. If respondents' primary considerations were broad spectrum coverage or antibiotic resistance they had 7.10 (p<0.001) and 12.51 (p<0.001) times the odds of using fortified vancomycin, respectively. Conclusion Practice patterns for the initial treatment of bacterial keratitis vary with clinicians in the USA being more likely to use fortified antibiotics versus fluoroquinolone monotherapy and more concerned with resistant organisms than their international peers.",
keywords = "Cornea, Infection",
author = "Ariana Austin and Julie Schallhorn and Mike Geske and Mannis, {Mark J} and Tom Lietman and Jennifer Rose-Nussbaumer",
year = "2017",
month = "8",
day = "1",
doi = "10.1136/bmjophth-2016-000047",
language = "English (US)",
volume = "2",
journal = "BMJ Open Ophthalmology",
issn = "2397-3269",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Empirical treatment of bacterial keratitis

T2 - An international survey of corneal specialists

AU - Austin, Ariana

AU - Schallhorn, Julie

AU - Geske, Mike

AU - Mannis, Mark J

AU - Lietman, Tom

AU - Rose-Nussbaumer, Jennifer

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background/aims New antibiotic agents and changing susceptibility patterns may have changed the empirical treatment of bacterial keratitis. Our objective in this study was to survey cornea specialists' practice patterns in the initial treatment of bacterial ulcers. Methods This study consisted of a short online survey emailed to members of the Cornea Society listserv for an international sample of cornea specialists. Data collection began July 2014 and ended October 2014. Results A total of 1009 surveys were emailed, and we received 140 (14%) responses. The majority of US clinicians surveyed (n=83, 80%) chose fortified antibiotics empirically, with 55% (n=57) selecting fortified vancomycin and 16% (n=17) using fluoroquinolone alone. International respondents were twice as likely to use fluoroquinolone monotherapy (31%, n=11, p=0.07) and less likely to use fortified vancomycin (33%, n=12, p=0.03). Forty-five per cent (n=46) of US respondents reported that their initial antibiotic choice covered methicillin-resistant Staphylococcus aureus, compared with 22% (n=8) of international respondents (p<0.01). Overall, respondents who were concerned about availability of antibiotics and toxicity were 20.86 (p<0.001) and 7.48 (p<0.001) times more likely to choose fluoroquinolone monotherapy, respectively. If respondents' primary considerations were broad spectrum coverage or antibiotic resistance they had 7.10 (p<0.001) and 12.51 (p<0.001) times the odds of using fortified vancomycin, respectively. Conclusion Practice patterns for the initial treatment of bacterial keratitis vary with clinicians in the USA being more likely to use fortified antibiotics versus fluoroquinolone monotherapy and more concerned with resistant organisms than their international peers.

AB - Background/aims New antibiotic agents and changing susceptibility patterns may have changed the empirical treatment of bacterial keratitis. Our objective in this study was to survey cornea specialists' practice patterns in the initial treatment of bacterial ulcers. Methods This study consisted of a short online survey emailed to members of the Cornea Society listserv for an international sample of cornea specialists. Data collection began July 2014 and ended October 2014. Results A total of 1009 surveys were emailed, and we received 140 (14%) responses. The majority of US clinicians surveyed (n=83, 80%) chose fortified antibiotics empirically, with 55% (n=57) selecting fortified vancomycin and 16% (n=17) using fluoroquinolone alone. International respondents were twice as likely to use fluoroquinolone monotherapy (31%, n=11, p=0.07) and less likely to use fortified vancomycin (33%, n=12, p=0.03). Forty-five per cent (n=46) of US respondents reported that their initial antibiotic choice covered methicillin-resistant Staphylococcus aureus, compared with 22% (n=8) of international respondents (p<0.01). Overall, respondents who were concerned about availability of antibiotics and toxicity were 20.86 (p<0.001) and 7.48 (p<0.001) times more likely to choose fluoroquinolone monotherapy, respectively. If respondents' primary considerations were broad spectrum coverage or antibiotic resistance they had 7.10 (p<0.001) and 12.51 (p<0.001) times the odds of using fortified vancomycin, respectively. Conclusion Practice patterns for the initial treatment of bacterial keratitis vary with clinicians in the USA being more likely to use fortified antibiotics versus fluoroquinolone monotherapy and more concerned with resistant organisms than their international peers.

KW - Cornea

KW - Infection

UR - http://www.scopus.com/inward/record.url?scp=85060771975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060771975&partnerID=8YFLogxK

U2 - 10.1136/bmjophth-2016-000047

DO - 10.1136/bmjophth-2016-000047

M3 - Review article

AN - SCOPUS:85060771975

VL - 2

JO - BMJ Open Ophthalmology

JF - BMJ Open Ophthalmology

SN - 2397-3269

IS - 1

M1 - e000047

ER -